A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
GlaxoSmithKline
GlaxoSmithKline
University of Hawaii
University of Southern California
GlaxoSmithKline
University of Oklahoma
iOnctura
Tesaro, Inc.
Beth Israel Deaconess Medical Center
University of Washington
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
Washington University School of Medicine
Tesaro, Inc.
M.D. Anderson Cancer Center
ARCAGY/ GINECO GROUP
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
Tesaro, Inc.
GlaxoSmithKline
University of Pittsburgh
Massachusetts General Hospital
GlaxoSmithKline
GlaxoSmithKline
Tesaro, Inc.
Dana-Farber Cancer Institute
GlaxoSmithKline
Grupo Español de Investigación en Cáncer de Ovario
University of Cincinnati
iTeos Therapeutics